Search results for " membranes" in Articles / App Notes
Article
Automated Concentration and Diafiltration of Multiple siRNA Samples
A team of scientists collaborated on a project to transfer a conventional manual concentration/diafiltration process for siRNA production.
ABSTRACT
The use of small-interf…
Article
Addressing the Challenges in Downstream Processing Today and Tomorrow
Newer classes of biotherapies will require innovations in processing technology.
By Glen R. Bolton, Bernard N. Violand, Richard S. Wright, Shujun Sun, Khurram M. Sunasara, Kathleen Watson, Johna…
Article
Advances in Sterilization Technologies for Overcoming Viral-Vector Manufacturing Challenges
She points to the development of smaller single-use mixers for small-volume applications, single-use filters and TFF membranes at various scales that are available or under development, and irradiated…
Article
A Closer Look at Affinity Ligands
Examples of affinity ligands that have been used for this purpose are lectins, which can interact with glycoproteins on cell membranes, and antibodies, which can bind to specific surface proteins. Wit…
Article
Paring Down Impurities in Downstream Processing
Myriad choices confront manufacturers before they even consider optimizing downstream processes. Each decision directly influences what final options will be available on arriving at the final…
Article
Cytiva Advances Fiber Chromatography Technology with New Launch
The technology involves the combination of high resin-binding capacity and the high flow rates of membranes in a scalable product that enables hundreds of cycles to be run in a single day, translating…
Article
Virus-like Particles as Therapeutic Moieties of the Future
Analytical and functional characterization of virus-like particles enables process reproducibility and product consistency.
By Ramesh Kumar, Manidipa Banerjee, Anurag S. Rathore
Virus-like…
Article
Gene Therapies Push Viral Vector Production
Gene Therapies Push Viral Vector Production
Viral vectors show promise as a delivery mechanism for gene therapy, but which virus types are commercially viable?
By Feliza Miraso…
Article
New Therapies Present Scaling Challenges
New Therapies Present Scaling Challenges
Manufacturing differences between traditional mAb therapies and newer biotherapeutics dictate whether processes should be scaled up, scaled out, or use an al…
Article
Moving PAT from Concept to Reality
These products are not well-characterized molecules like monoclonal antibodies, but a complex of various proteins, DNA/RNA, and in some cases lipid membranes. “This complexity makes it hard to identif…